Cutaneous gene delivery

Journal of Dermatological Science

Volumn 50, Issue 2, 2008, Pages 87-98

  Kikuchi, Yasushi ^a   Tamai, Katsuto ^a   Kaneda, Yasufumi ^a  

^a OSAKA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

Barrier function; Gene therapy; Genodermatosis

Indexed keywords

ADENOSINE DEAMINASE; ADENOVIRUS VECTOR; ANTISENSE OLIGONUCLEOTIDE; BETA4 INTEGRIN; BLOOD CLOTTING FACTOR 9; COLLAGEN; COLLAGEN TYPE 17 ALPHA1; COLLAGEN TYPE 7 ALPHA1; ERYTHROPOIETIN; FATTY ALDEHYDE DEHYDROGENASE; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; GROWTH HORMONE; GUANOSINE TRIPHOSPHATE CYCLOHYDROLASE I; INTERLEUKIN 10; INTERLEUKIN 4; INTERLEUKIN 6; LAMININ; LAMININ BETA3; LENTIVIRUS VECTOR; LEPTIN; LIPOSOME; ORNITHINE OXOACID AMINOTRANSFERASE; PARVOVIRUS VECTOR; PHENYLALANINE 4 MONOOXYGENASE; PROTEIN GLUTAMINE GAMMA GLUTAMYLTRANSFERASE; RETROVIRUS VECTOR; STERYL SULFATASE; TRANSFORMING GROWTH FACTOR BETA; TRANSGLUTAMINASE 1; UNCLASSIFIED DRUG; UNINDEXED DRUG;

ATOPIC DERMATITIS; EPIDERMOLYSIS BULLOSA; GENE DELIVERY SYSTEM; GENE EXPRESSION; GENE STRUCTURE; GENE TARGETING; GENE TRANSFER; GENETIC STABILITY; GENODERMATOSIS; HUMAN; IMMUNE RESPONSE; IN VIVO STUDY; KERATINOCYTE; LAMELLAR ICHTHYOSIS; LIPOSOMAL GENE DELIVERY SYSTEM; NONHUMAN; NONVIRAL GENE DELIVERY SYSTEM; NONVIRAL GENE THERAPY; PRIORITY JOURNAL; REVIEW; SKIN; SKIN FUNCTION; SKIN STRUCTURE; STEM CELL GENE THERAPY; TISSUE ENGINEERING; TRANSGENE; VIRAL GENE DELIVERY SYSTEM; VIRAL GENE THERAPY; X LINKED ICHTHYOSIS; X LINKED SEVERE COMBINED IMMUNODEFICIENCY;

ANIMALS; DNA; GENE THERAPY; GENE TRANSFER TECHNIQUES; HUMANS; KERATINOCYTES; PERMEABILITY; SKIN; SKIN ABSORPTION; SKIN DISEASES, GENETIC;

EID: 41149141003     PISSN: 09231811     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jdermsci.2007.07.006     Document Type: Review

References (90)

1. Ito M., Liu Y., Yang Z., et al. Stem cells in the hair follicle bulge contribute to wound repair but not to homeostasis of the epidermis. Nat Med 11 12 (2005) 1351-1354
2. Bos J.D., and Meinardi M.M. The 500 Dalton rule for the skin penetration of chemical compounds and drugs. Exp Dermatol 9 3 (2000) 165-169
3. Furuse M., Fujita K., Hiiragi T., Fujimoto K., and Tsukita S. Claudin-1 and -2: novel integral membrane proteins localizing at tight junctions with no sequence similarity to occludin. J Cell Biol 141 7 (1998) 1539-1550
4. Furuse M., Hata M., Furuse K., et al. Claudin-based tight junctions are crucial for the mammalian epidermal barrier: a lesson from claudin-1-deficient mice. J Cell Biol 156 6 (2002) 1099-1111
5. Elias P.M., Matsuyoshi N., Wu H., et al. Desmoglein isoform distribution affects stratum corneum structure and function. J Cell Biol 153 2 (2001) 243-249
6. Gerrard A.J., Hudson D.L., Brownlee G.G., and Watt F.M. Towards gene therapy for haemophilia B using primary human keratinocytes. Nat Genet 3 2 (1993) 180-183
7. Ghazizadeh S., Kalish R.S., and Taichman L.B. Immune-mediated loss of transgene expression in skin: implications for cutaneous gene therapy. Mol Ther 7 3 (2003) 296-303
8. Hacein-Bey-Abina S., von Kalle C., Schmidt M., et al. A serious adverse event after successful gene therapy for X-linked severe combined immunodeficiency. N Engl J Med 348 3 (2003) 255-256
9. Mavilio F., Pellegrini G., Ferrari S., et al. Correction of junctional epidermolysis bullosa by transplantation of genetically modified epidermal stem cells. Nat Med 12 12 (2006) 1397-1402
10. St. George J.A. Gene therapy progress and prospects: adenoviral vectors. Gene Ther 10 14 (2003) 1135-1141
11. Raper S.E., Chirmule N., Lee F.S., et al. Fatal systemic inflammatory response syndrome in a ornithine transcarbamylase deficient patient following adenoviral gene transfer. Mol Genet Metab 80 1-2 (2003) 148-158
12. Hidaka C., Milano E., Leopold P.L., et al. CAR-dependent and CAR-independent pathways of adenovirus vector-mediated gene transfer and expression in human fibroblasts. J Clin Invest 103 4 (1999) 579-587
13. Huber M., Limat A., Wagner E., and Hohl D. Efficient in vitro transfection of human keratinocytes with an adenovirus-enhanced receptor-mediated system. J Invest Dermatol 114 4 (2000) 661-666
14. Arcasoy S.M., Latoche J.D., Gondor M., Pitt B.R., and Pilewski J.M. Polycations increase the efficiency of adenovirus-mediated gene transfer to epithelial and endothelial cells in vitro. Gene Ther 4 1 (1997) 32-38
15. Stoff A., Rivera A.A., Banerjee N.S., et al. Strategies to enhance transductional efficiency of adenoviral-based gene transfer to primary human fibroblasts and keratinocytes as a platform in dermal wounds. Wound Repair Regen 14 5 (2006) 608-617
16. Buning H., Braun-Falco M., and Hallek M. Progress in the use of adeno-associated viral vectors for gene therapy. Cells Tissues Organs 177 3 (2004) 139-150
17. Meyers C., Mane M., Kokorina N., Alam S., and Hermonat P.L. Ubiquitous human adeno-associated virus type 2 autonomously replicates in differentiating keratinocytes of a normal skin model. Virology 272 2 (2000) 338-346
18. Naldini L., Blomer U., Gallay P., et al. In vivo gene delivery and stable transduction of nondividing cells by a lentiviral vector. Science 272 5259 (1996) 263-267
19. Ortiz-Urda S., Thyagarajan B., Keene D.R., et al. Stable nonviral genetic correction of inherited human skin disease. Nat Med 8 10 (2002) 1166-1170
20. Ortiz-Urda S., Lin Q., Yant S.R., Keene D., Kay M.A., and Khavari P.A. Sustainable correction of junctional epidermolysis bullosa via transposon-mediated nonviral gene transfer. Gene Ther 10 13 (2003) 1099-1104
21. Li L., and Hoffman R.M. The feasibility of targeted selective gene therapy of the hair follicle. Nat Med 1 7 (1995) 705-706
22. Kaneda Y., Iwai K., and Uchida T. Increased expression of DNA cointroduced with nuclear protein in adult rat liver. Science 243 4889 (1989) 375-378
23. Hayashi S.I., Morishita R., Aoki M., et al. In vivo transfer of gene and oligodeoxynucleotides into skin of fetal rats by incubation in amniotic fluid. Gene Ther 3 10 (1996) 878-885
24. Tang D.C., Shi Z., and Curiel D.T. Vaccination onto bare skin. Nature 388 6644 (1997) 729-730
25. Fan H., Lin Q., Morrissey G.R., and Khavari P.A. Immunization via hair follicles by topical application of naked DNA to normal skin. Nat Biotechnol 17 9 (1999) 870-872
26. Morishita R., Sugimoto T., Aoki M., et al. In vivo transfection of cis element "decoy" against nuclear factor-kappaB binding site prevents myocardial infarction. Nat Med 3 8 (1997) 894-899
27. Nakamura H., Aoki M., Tamai K., et al. Prevention and regression of atopic dermatitis by ointment containing NFκB decoy oligodeoxynucleotides in NC/Nga atopic mouse model. Gene Ther 9 18 (2002) 1221-1229
28. Hengge U.R., Chan E.F., Foster R.A., Walker P.S., and Vogel J.C. Cytokine gene expression in epidermis with biological effects following injection of naked DNA. Nat Genet 10 2 (1995) 161-166
29. Meng X., Sawamura D., Tamai K., Hanada K., Ishida H., and Hashimoto I. Keratinocyte gene therapy for systemic diseases. Circulating interleukin 10 released from gene-transferred keratinocytes inhibits contact hypersensitivity at distant areas of the skin. J Clin Invest 101 6 (1998) 1462-1467
30. Sawamura D., Yasukawa K., Kodama K., et al. The majority of keratinocytes incorporate intradermally injected plasmid DNA regardless of size but only a small proportion of cells can express the gene product. J Invest Dermatol 118 6 (2002) 967-971
31. Woodley D.T., Keene D.R., Atha T., et al. Intradermal injection of lentiviral vectors corrects regenerated human dystrophic epidermolysis bullosa skin tissue in vivo. Mol Ther 10 2 (2004) 318-326
32. Marchetto M.C., Muotri A.R., Burns D.K., Friedberg E.C., and Menck C.F. Gene transduction in skin cells: preventing cancer in xeroderma pigmentosum mice. Proc Natl Acad Sci USA 101 51 (2004) 17759-17764
33. Titomirov A.V., Sukharev S., and Kistanova E. In vivo electroporation and stable transformation of skin cells of newborn mice by plasmid DNA. Biochim Biophys Acta 1088 1 (1991) 131-134
34. Marti G., Ferguson M., Wang J., et al. Electroporative transfection with KGF-1 DNA improves wound healing in a diabetic mouse model. Gene Ther 11 24 (2004) 1780-1785
35. Drabick J.J., Glasspool-Malone J., King A., and Malone R.W. Cutaneous transfection and immune responses to intradermal nucleic acid vaccination are significantly enhanced by in vivo electropermeabilization. Mol Ther 3 2 (2001) 249-255
36. Dujardin N., Van Der Smissen P., and Preat V. Topical gene transfer into rat skin using electroporation. Pharm Res 18 1 (2001) 61-66
37. Sakamoto T., Miyazaki E., Aramaki Y., et al. Improvement of dermatitis by iontophoretically delivered antisense oligonucleotides for interleukin-10 in NC/Nga mice. Gene Ther 11 3 (2004) 317-324
38. Endoh M., Koibuchi N., Sato M., et al. Fetal gene transfer by intrauterine injection with microbubble-enhanced ultrasound. Mol Ther 5 5 Pt 1 (2002) 501-508
39. Williams R.S., Johnston S.A., Riedy M., DeVit M.J., McElligott S.G., and Sanford J.C. Introduction of foreign genes into tissues of living mice by DNA-coated microprojectiles. Proc Natl Acad Sci USA 88 7 (1991) 2726-2730
40. Sun W.H., Burkholder J.K., Sun J., et al. In vivo cytokine gene transfer by gene gun reduces tumor growth in mice. Proc Natl Acad Sci USA 92 7 (1995) 2889-2893
41. Fuller D.H., Loudon P., and Schmaljohn C. Preclinical and clinical progress of particle-mediated DNA vaccines for infectious diseases. Methods 40 1 (2006) 86-97
42. Prausnitz M.R., Bose V.G., Langer R., and Weaver J.C. Electroporation of mammalian skin: a mechanism to enhance transdermal drug delivery. Proc Natl Acad Sci USA 90 22 (1993) 10504-10508
43. Lombry C., Dujardin N., and Preat V. Transdermal delivery of macromolecules using skin electroporation. Pharm Res 17 1 (2000) 32-37
44. Kalia Y.N., Naik A., Garrison J., and Guy R.H. Iontophoretic drug delivery. Adv Drug Deliv Rev 56 5 (2004) 619-658
45. Wang Y., Thakur R., Fan Q., and Michniak B. Transdermal iontophoresis: combination strategies to improve transdermal iontophoretic drug delivery. Eur J Pharm Biopharm 60 2 (2005) 179-191
46. Mitragotri S. Healing sound: the use of ultrasound in drug delivery and other therapeutic applications. Nat Rev Drug Discov 4 3 (2005) 255-260
47. Marjukka Suhonen T., Bouwstra J.A., and Urtti A. Chemical enhancement of percutaneous absorption in relation to stratum corneum structural alterations. J Control Release 59 2 (1999) 149-161
48. Karande P., Jain A., and Mitragotri S. Discovery of transdermal penetration enhancers by high-throughput screening. Nat Biotechnol 22 2 (2004) 192-197
49. Sivamani R.K., Liepmann D., and Maibach H.I. Microneedles and transdermal applications. Expert Opin Drug Deliv 4 1 (2007) 19-25
50. Mikszta J.A., Alarcon J.B., Brittingham J.M., Sutter D.E., Pettis R.J., and Harvey N.G. Improved genetic immunization via micromechanical disruption of skin-barrier function and targeted epidermal delivery. Nat Med 8 4 (2002) 415-419
51. Gross D.A., Leboeuf M., Gjata B., Danos O., and Davoust J. CD4+CD25+ regulatory T cells inhibit immune-mediated transgene rejection. Blood 102 13 (2003) 4326-4328
52. Andersson G., Denaro M., Johnson K., et al. Engraftment of retroviral EGFP-transduced bone marrow in mice prevents rejection of EGFP-transgenic skin grafts. Mol Ther 8 3 (2003) 385-391
53. Dellambra E., Vailly J., Pellegrini G., et al. Corrective transduction of human epidermal stem cells in laminin-5-dependent junctional epidermolysis bullosa. Hum Gene Ther 9 9 (1998) 1359-1370
54. Vailly J., Gagnoux-Palacios L., Dell'Ambra E., et al. Corrective gene transfer of keratinocytes from patients with junctional epidermolysis bullosa restores assembly of hemidesmosomes in reconstructed epithelia. Gene Ther 5 10 (1998) 1322-1332
55. Seitz C.S., Giudice G.J., Balding S.D., Marinkovich M.P., and Khavari P.A. BP180 gene delivery in junctional epidermolysis bullosa. Gene Ther 6 1 (1999) 42-47
56. Robbins P.B., Lin Q., Goodnough J.B., Tian H., Chen X., and Khavari P.A. In vivo restoration of laminin 5 beta 3 expression and function in junctional epidermolysis bullosa. Proc Natl Acad Sci USA 98 9 (2001) 5193-5198
57. Dellambra E., Prislei S., Salvati A.L., et al. Gene correction of integrin beta4-dependent pyloric atresia-junctional epidermolysis bullosa keratinocytes establishes a role for beta4 tyrosines 1422 and 1440 in hemidesmosome assembly. J Biol Chem 276 44 (2001) 41336-41342
58. Ortiz-Urda S., Thyagarajan B., Keene D.R., Lin Q., Calos M.P., and Khavari P.A. PhiC31 integrase-mediated nonviral genetic correction of junctional epidermolysis bullosa. Hum Gene Ther 14 9 (2003) 923-928
59. Spirito F., Capt A., Del Rio M., et al. Sustained phenotypic reversion of junctional epidermolysis bullosa dog keratinocytes: establishment of an immunocompetent animal model for cutaneous gene therapy. Biochem Biophys Res Commun 339 3 (2006) 769-778
60. Muhle C., Neuner A., Park J., et al. Evaluation of prenatal intra-amniotic LAMB3 gene delivery in a mouse model of Herlitz disease. Gene Ther 13 23 (2006) 1665-1676
61. Chen M., O'Toole E.A., Muellenhoff M., Medina E., Kasahara N., and Woodley D.T. Development and characterization of a recombinant truncated type VII collagen "minigene". Implication for gene therapy of dystrophic epidermolysis bullosa. J Biol Chem 275 32 (2000) 24429-24435
62. Chen M., Kasahara N., Keene D.R., et al. Restoration of type VII collagen expression and function in dystrophic epidermolysis bullosa. Nat Genet 32 4 (2002) 670-675
63. Ortiz-Urda S., Lin Q., Green C.L., Keene D.R., Marinkovich M.P., and Khavari P.A. Injection of genetically engineered fibroblasts corrects regenerated human epidermolysis bullosa skin tissue. J Clin Invest 111 2 (2003) 251-255
64. Baldeschi C., Gache Y., Rattenholl A., et al. Genetic correction of canine dystrophic epidermolysis bullosa mediated by retroviral vectors. Hum Mol Genet 12 15 (2003) 1897-1905
65. Woodley D.T., Krueger G.G., Jorgensen C.M., et al. Normal and gene-corrected dystrophic epidermolysis bullosa fibroblasts alone can produce type VII collagen at the basement membrane zone. J Invest Dermatol 121 5 (2003) 1021-1028
66. Gache Y., Baldeschi C., Del Rio M., et al. Construction of skin equivalents for gene therapy of recessive dystrophic epidermolysis bullosa. Hum Gene Ther 15 10 (2004) 921-933
67. Goto M., Sawamura D., Ito K., et al. Fibroblasts show more potential as target cells than keratinocytes in COL7A1 gene therapy of dystrophic epidermolysis bullosa. J Invest Dermatol 126 4 (2006) 766-772
68. Goto M., Sawamura D., Nishie W., et al. Targeted skipping of a single exon harboring a premature termination codon mutation: implications and potential for gene correction therapy for selective dystrophic epidermolysis bullosa patients. J Invest Dermatol 126 12 (2006) 2614-2620
69. Choate K.A., Kinsella T.M., Williams M.L., Nolan G.P., and Khavari P.A. Transglutaminase 1 delivery to lamellar ichthyosis keratinocytes. Hum Gene Ther 7 18 (1996) 2247-2253
70. Haug S., and Braun-Falco M. Restoration of fatty aldehyde dehydrogenase deficiency in Sjogren-Larsson syndrome. Gene Ther 13 13 (2006) 1021-1026
71. Jensen T.G., Jensen U.B., Jensen P.K., et al. Correction of steroid sulfatase deficiency by gene transfer into basal cells of tissue-cultured epidermis from patients with recessive X-linked ichthyosis. Exp Cell Res 209 2 (1993) 392-397
72. Freiberg R.A., Choate K.A., Deng H., Alperin E.S., Shapiro L.J., and Khavari P.A. A model of corrective gene transfer in X-linked ichthyosis. Hum Mol Genet 6 6 (1997) 927-933
73. Carreau M., Quilliet X., Eveno E., et al. Functional retroviral vector for gene therapy of xeroderma pigmentosum group D patients. Hum Gene Ther 6 10 (1995) 1307-1315
74. Zeng L., Quilliet X., Chevallier-Lagente O., Eveno E., Sarasin A., and Mezzina M. Retrovirus-mediated gene transfer corrects DNA repair defect of xeroderma pigmentosum cells of complementation groups A, B and C. Gene Ther 4 10 (1997) 1077-1084
75. Marchetto M.C., Correa R.G., Menck C.F., and Muotri A.R. Functional lentiviral vectors for xeroderma pigmentosum gene therapy. J Biotechnol 126 4 (2006) 424-430
76. Descamps V., Blumenfeld N., Beuzard Y., and Perricaudet M. Keratinocytes as a target for gene therapy. Sustained production of erythropoietin in mice by human keratinocytes transduced with an adenoassociated virus vector. Arch Dermatol 132 10 (1996) 1207-1211
77. Fenjves E.S., Schwartz P.M., Blaese R.M., and Taichman L.B. Keratinocyte gene therapy for adenosine deaminase deficiency: a model approach for inherited metabolic disorders. Hum Gene Ther 8 8 (1997) 911-917
78. Page S.M., and Brownlee G.G. An ex vivo keratinocyte model for gene therapy of hemophilia B. J Invest Dermatol 109 2 (1997) 139-145
79. Jensen T.G., Sullivan D.M., Morgan R.A., et al. Retrovirus-mediated gene transfer of ornithine-delta-aminotransferase into keratinocytes from gyrate atrophy patients. Hum Gene Ther 8 17 (1997) 2125-2132
80. Sullivan D.M., Jensen T.G., Taichman L.B., and Csaky K.G. Ornithine-delta-aminotransferase expression and ornithine metabolism in cultured epidermal keratinocytes: toward metabolic sink therapy for gyrate atrophy. Gene Ther 4 10 (1997) 1036-1044
81. Page S.M., and Brownlee G.G. Differentiation-specific enhancer activity in transduced keratinocytes: a model for epidermal gene therapy. Gene Ther 5 3 (1998) 394-402
82. Christensen R., Kolvraa S., Blaese R.M., and Jensen T.G. Development of a skin-based metabolic sink for phenylalanine by overexpression of phenylalanine hydroxylase and GTP cyclohydrolase in primary human keratinocytes. Gene Ther 7 23 (2000) 1971-1978
83. Larcher F., Del Rio M., Serrano F., et al. A cutaneous gene therapy approach to human leptin deficiencies: correction of the murine ob/ob phenotype using leptin-targeted keratinocyte grafts. FASEB J 15 9 (2001) 1529-1538
84. Beak S.C., Lin Q., Robbins P.B., Fan H., and Khavari P.A. Sustainable systemic delivery via a single injection of lentivirus into human skin tissue. Hum Gene Ther 12 12 (2001) 1551-1558
85. Christensen R., Guttler F., and Jensen T.G. Comparison of epidermal keratinocytes and dermal fibroblasts as potential target cells for somatic gene therapy of phenylketonuria. Mol Genet Metab 76 4 (2002) 313-318
86. Meng X., Sawamura D., Ina S., Tamai K., Hanada K., and Hashimoto I. Keratinocyte gene therapy: cytokine gene expression in local keratinocytes and in circulation by introducing cytokine genes into skin. Exp Dermatol 11 5 (2002) 456-461
87. Bellini M.H., Peroni C.N., and Bartolini P. Increases in weight of growth hormone-deficient and immunodeficient (lit/scid) dwarf mice after grafting of hGH-secreting, primary human keratinocytes. FASEB J 17 15 (2003) 2322-2324
88. Agrawal N., You H., Liu Y., et al. Generation of recombinant skin in vitro by adeno-associated virus type 2 vector transduction. Tissue Eng 10 11-12 (2004) 1707-1715
89. Peroni C.N., Cecchi C.R., Damiani R., et al. High-level secretion of growth hormone by retrovirally transduced primary human keratinocytes: prospects for an animal model of cutaneous gene therapy. Mol Biotechnol 34 2 (2006) 239-245
90. Lei P., Ogunade A., Kirkwood K.L., Laychock S.G., and Andreadis S.T. Efficient production of bioactive insulin from human epidermal keratinocytes and tissue-engineered skin substitutes: implications for treatment of diabetes. Tissue Eng (2007)